Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression

Carmelo Scarpignato, Luigi Gatta, Angelo Zullo, Corrado Blandizzi, SIF-AIGO-FIMMG Group, Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners, Carmelo Scarpignato, Corrado Blandizzi, Luigi Gatta, Angelo Zullo, Anna Kohn, Gioacchino Leandro, Antonio Balzano, Alberto Chiriatti, Walter Marocco, Carmelo Scarpignato, Luigi Gatta, Angelo Zullo, Corrado Blandizzi, SIF-AIGO-FIMMG Group, Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners, Carmelo Scarpignato, Corrado Blandizzi, Luigi Gatta, Angelo Zullo, Anna Kohn, Gioacchino Leandro, Antonio Balzano, Alberto Chiriatti, Walter Marocco

Abstract

Background: The introduction of proton pump inhibitors (PPIs) into clinical practice has revolutionized the management of acid-related diseases. Studies in primary care and emergency settings suggest that PPIs are frequently prescribed for inappropriate indications or for indications where their use offers little benefit. Inappropriate PPI use is a matter of great concern, especially in the elderly, who are often affected by multiple comorbidities and are taking multiple medications, and are thus at an increased risk of long-term PPI-related adverse outcomes as well as drug-to-drug interactions. Herein, we aim to review the current literature on PPI use and develop a position paper addressing the benefits and potential harms of acid suppression with the purpose of providing evidence-based guidelines on the appropriate use of these medications.

Methods: The topics, identified by a Scientific Committee, were assigned to experts selected by three Italian Scientific Societies, who independently performed a systematic search of the relevant literature using Medline/PubMed, Embase, and the Cochrane databases. Search outputs were distilled, paying more attention to systematic reviews and meta-analyses (where available) representing the best evidence. The draft prepared on each topic was circulated amongst all the members of the Scientific Committee. Each expert then provided her/his input to the writing, suggesting changes and the inclusion of new material and/or additional relevant references. The global recommendations were then thoroughly discussed in a specific meeting, refined with regard to both content and wording, and approved to obtain a summary of current evidence.

Results: Twenty-five years after their introduction into clinical practice, PPIs remain the mainstay of the treatment of acid-related diseases, where their use in gastroesophageal reflux disease, eosinophilic esophagitis, Helicobacter pylori infection, peptic ulcer disease and bleeding as well as, and Zollinger-Ellison syndrome is appropriate. Prevention of gastroduodenal mucosal lesions (and symptoms) in patients taking non-steroidal anti-inflammatory drugs (NSAIDs) or antiplatelet therapies and carrying gastrointestinal risk factors also represents an appropriate indication. On the contrary, steroid use does not need any gastroprotection, unless combined with NSAID therapy. In dyspeptic patients with persisting symptoms, despite successful H. pylori eradication, short-term PPI treatment could be attempted. Finally, addition of PPIs to pancreatic enzyme replacement therapy in patients with refractory steatorrhea may be worthwhile.

Conclusions: Overall, PPIs are irreplaceable drugs in the management of acid-related diseases. However, PPI treatment, as any kind of drug therapy, is not without risk of adverse effects. The overall benefits of therapy and improvement in quality of life significantly outweigh potential harms in most patients, but those without clear clinical indication are only exposed to the risks of PPI prescription. Adhering with evidence-based guidelines represents the only rational approach to effective and safe PPI therapy. Please see related Commentary: doi: 10.1186/s12916-016-0724-1 .

Keywords: Acid-related diseases; Antisecretory drugs; Appropriateness; Efficacy; Proton pump inhibitors; Safety.

References

    1. Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: where do we go from here? Dig Dis. 2006;24:11–46. doi: 10.1159/000091298.
    1. Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005;22(Suppl 3):10–9. doi: 10.1111/j.1365-2036.2005.02715.x.
    1. Scarpignato C, Pelosini I. Review article: the opportunities and benefits of extended acid suppression. Aliment Pharmacol Ther. 2006;23(Suppl 2):23–34. doi: 10.1111/j.1365-2036.2006.02945.x.
    1. Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol. 2008;8:677–84. doi: 10.1016/j.coph.2008.09.004.
    1. Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol. 2015;6 doi: 10.1038/ctg.2015.39.
    1. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 2012;72:437–45. doi: 10.2165/11599320-000000000-00000.
    1. Lanas A. We are using too many PPIs, and we need to stop: A European perspective. Am J Gastroenterol. 2016;111:1085–6. doi: 10.1038/ajg.2016.166.
    1. Galmiche JP. Traitement de l'oesophagite de reflux par les inhibiteurs de pompe à protons: de l'efficacité à la dépendance. Hépato-Gastro Oncol Digest. 1995;2:215–9.
    1. Boath EH, Blenkinsopp A. The rise and rise of proton pump inhibitor drugs: patients' perspectives. Soc Sci Med. 1997;45:1571–9. doi: 10.1016/S0277-9536(97)00094-4.
    1. Pottegård A, Broe A, Hallas J, de Muckadell OBS, Lassen AT, Lødrup AB. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther Adv Gastroenterol. 2016;9:671–8. doi: 10.1177/1756283X16650156.
    1. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012;5:219–32. doi: 10.1177/1756283X12437358.
    1. Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103:207–11. doi: 10.1097/SMJ.0b013e3181ce0e7a.
    1. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66:1265–71. doi: 10.1007/s00228-010-0871-9.
    1. Parente F, Cucino C, Gallus S, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther. 2003;17:1503–6. doi: 10.1046/j.1365-2036.2003.01600.x.
    1. Wermeling M, Himmel W, Behrens G, Ahrens D. Why do GPs continue inappropriate hospital prescriptions of proton pump inhibitors? A qualitative study. Eur J Gen Pract. 2014;20:174–80. doi: 10.3109/13814788.2013.844787.
    1. Cammarota S, Bruzzese D, Sarnelli G, et al. Proton pump inhibitors prescribing following the introduction of generic drugs. Eur J Clin Invest. 2012;42:1068–78. doi: 10.1111/j.1365-2362.2012.02696.x.
    1. Inadomi JM, Fendrick AM. PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol. 2005;3:208–15. doi: 10.1016/S1542-3565(04)00717-7.
    1. Haag S, Andrews JM, Katelaris PH, et al. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. Digestion. 2009;80:226–34. doi: 10.1159/000235953.
    1. Boardman HF, Delaney BC, Haag S. Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors. Curr Med Res Opin. 2015;31:1309–18. doi: 10.1185/03007995.2015.1047745.
    1. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;30:911–8. doi: 10.2165/00002018-200730100-00009.
    1. Marengoni A, Pasina L, Concoreggi C, et al. Understanding adverse drug reactions in older adults through drug-drug interactions. Eur J Intern Med. 2014;25:843–6. doi: 10.1016/j.ejim.2014.10.001.
    1. Blandizzi C, Scarpignato C. Gastrointestinal drugs. Side Eff Drugs Ann. 2011;34:741–67. doi: 10.1016/B978-0-444-53741-6.00036-2.
    1. Blandizzi C, Scarpignato C. Gastrointestinal drugs. Side Eff Drugs Ann. 2012;35:555–78. doi: 10.1016/B978-0-444-59499-0.00036-2.
    1. Blandizzi C, Scarpignato C. Gastrointestinal drugs. Side Eff Drugs Ann. 2014;36:633–58. doi: 10.1016/B978-0-444-62635-6.00036-X.
    1. Blandizzi C, Scarpignato C. Gastrointestinal drugs. Side Eff Drugs Ann. 2014;37:539–60. doi: 10.1016/B978-0-444-63407-8.00036-8.
    1. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) Ann Rheum Dis. 2000;59:936–44. doi: 10.1136/ard.59.12.936.
    1. Schnitzer TJ. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage. 2002;23(4 Suppl):S24–30. doi: 10.1016/S0885-3924(02)00372-X.
    1. Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis - An expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015;13:55. doi: 10.1186/s12916-015-0285-8.
    1. Bianco MA, Rotondano G, Buri L, Tessari F, Cipolletta L, . Italian G Gastro-protective strategies in primary care in Italy: the "." survey. Dig Liver Dis. 2010;42:359–64. doi: 10.1016/j.dld.2009.11.003.
    1. Morini S, Zullo A, Oliveti D, et al. A very high rate of inappropriate use of gastroprotection for nonsteroidal anti-inflammatory drug therapy in primary care: a cross-sectional study. J Clin Gastroenterol. 2011;45:780–4. doi: 10.1097/MCG.0b013e3182151be7.
    1. Montagnani S, Tuccori M, Testi A, et al. Adherence with regulatory resolutions on prevention of NSAIDs-related gastrointestinal injury in Italy. Int J Clin Pharm. 2016;38:829–37. doi: 10.1007/s11096-016-0291-8.
    1. OECD.Stat. . Accessed on 4 July 2016.
    1. Ladd AM, Panagopoulos G, Cohen J, Mar N, Graham R. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347:446–51. doi: 10.1097/MAJ.0b013e31829f87d5.
    1. Kahrilas PJ. GERD pathogenesis, pathophysiology, and clinical manifestations. Cleve Clin J Med. 2003;70(Suppl 5):S4–19. doi: 10.3949/ccjm.70.Suppl_5.S4.
    1. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut. 1999;44(Suppl 2):S1–16. doi: 10.1136/gut.44.2008.S1.
    1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20. doi: 10.1111/j.1572-0241.2006.00630.x.
    1. Modlin IM, Hunt RH, Malfertheiner P, et al. Diagnosis and management of non-erosive reflux disease - the Vevey NERD Consensus Group. Digestion. 2009;80:74–88. doi: 10.1159/000219365.
    1. Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol. 2013;10:371–80. doi: 10.1038/nrgastro.2013.50.
    1. Boeckxstaens GE, Rohof WO. Pathophysiology of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2014;43:15–25. doi: 10.1016/j.gtc.2013.11.001.
    1. Kahrilas PJ, McColl K, Fox M, et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol. 2013;108:1058–64. doi: 10.1038/ajg.2013.132.
    1. Anand G, Katz PO. Gastroesophageal reflux disease and obesity. Gastroenterol Clin North Am. 2010;39:39–46. doi: 10.1016/j.gtc.2009.12.002.
    1. Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014;43:161–73. doi: 10.1016/j.gtc.2013.11.009.
    1. Galmiche JP, Letessier E, Scarpignato C. Treatment of gastro-oesophageal reflux disease in adults. BMJ. 1998;316:1720–3. doi: 10.1136/bmj.316.7146.1720.
    1. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59:135–53. doi: 10.1016/j.phrs.2008.09.016.
    1. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007;2
    1. Edwards SJ, Lind T, Lundell L. Systematic review: Proton pump inhibitors (PPIs) for the healing of reflux oesophagitis – A comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther. 2006;24:743–50. doi: 10.1111/j.1365-2036.2006.03074.x.
    1. Yuan Y, Vinh B, Hunt RH. Non-healed rate of moderate-severe (LA Classification Grade C and D) erosive esophagitis after 4-8 weeks proton pump inhibitors (PPIs): Evidence of an unmet need. Gastroenterology. 2009;136 Suppl 1:A-440.
    1. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452–8. doi: 10.1016/j.cgh.2006.09.013.
    1. Labenz J, Armstrong D, Leodolter A, Baldycheva I. Management of reflux esophagitis: does the choice of proton pump inhibitor matter? Int J Clin Pract. 2015;69:796–801. doi: 10.1111/ijcp.12623.
    1. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology. 1996;111:85–92. doi: 10.1053/gast.1996.v111.pm8698230.
    1. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–80. doi: 10.1136/gut.45.2.172.
    1. Iwakiri K, Umegaki E, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (20 mg once-daily) compared to lansoprazole (30 mg once-daily) in patients with erosive esophagitis. Gastroenterology. 2014;146:S-741. doi: 10.1016/S0016-5085(14)62682-2.
    1. Umegaki E, Iwakiri K, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg Once-Daily) compared to lansoprazole (15 mg Once-Daily) in a 24-week maintenance treatment for healed erosive esophagitis. Gastroenterology. 2014;146:S-738. doi: 10.1016/S0016-5085(14)62675-5.
    1. Miner P, Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98:2616–20. doi: 10.1111/j.1572-0241.2003.08783.x.
    1. Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60:531–9. doi: 10.1007/s00228-004-0804-6.
    1. Miner P, Katz PO, Chen Y, Sostek M. Reanalysis of intragastric pH results based on updated correction factors for slimline[reg] and zinetics[trade] 24 single-use pH catheters. Am J Gastroenterol. 2006;101:404–5. doi: 10.1111/j.1572-0241.2006.00401_3.x.
    1. Goldstein JL, Miner PB, Jr, Schlesinger PK, Liu S, Silberg DG. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther. 2006;23:1189–96. doi: 10.1111/j.1365-2036.2006.02867.x.
    1. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65:19–31. doi: 10.1007/s00228-008-0576-5.
    1. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5
    1. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1419–25. doi: 10.1038/ajg.2011.146.
    1. Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747–57. doi: 10.1111/j.1365-2982.2012.01888.x.
    1. Scarpignato C. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil. 2012;24:697–704. doi: 10.1111/j.1365-2982.2012.01977.x.
    1. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Esophageal disorders. Gastroenterology. 2016;150:1368–79. doi: 10.1053/j.gastro.2016.02.012.
    1. Weijenborg PW, de Schepper HS, Smout AJ, Bredenoord AJ. Effects of antidepressants in patients with functional esophageal disorders or gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2015;13:251–9. e1. doi: 10.1016/j.cgh.2014.06.025.
    1. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635–43. doi: 10.1111/apt.12007.
    1. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473–7. doi: 10.1111/j.1365-2036.2006.02911.x.
    1. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18:370–3. doi: 10.1111/j.1442-2050.2005.00518.x.
    1. Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev. 2009;4
    1. Scarpignato C. Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle. Dig Liver Dis. 2005;37:468–74. doi: 10.1016/j.dld.2005.03.002.
    1. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119–24. doi: 10.1097/00042737-199802000-00004.
    1. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005;2
    1. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. J Outc Resear. 2002;6:1–14.
    1. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: The LOTUS randomized clinical trial. JAMA. 2011;305:1969–77. doi: 10.1001/jama.2011.626.
    1. Lundell L, Miettinen P, Myrvold HE, et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009;7:1292–8. doi: 10.1016/j.cgh.2009.05.021.
    1. Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol. 2010;24:905–21. doi: 10.1016/j.bpg.2010.09.004.
    1. Contini S, Scarpignato C. Evaluation of clinical outcome after laparoscopic antireflux surgery in clinical practice: still a controversial issue. Minim Invasive Surg. 2011;2011:725472.
    1. Yuan Y, Dattani ND, Scarpignato C, Hunt RH. Use of antisecretory medication after antireflux surgery for patients with gastroesophageal reflux disease (GERD): a systematic review of randomized control trials (RCTs) Am J Gastroenterol. 2009;104 Suppl 3:S25.
    1. Yuan Y, Dattani ND, Scarpignato C, Hunt RH. Use of antisecretory medication (ARM) after antireflux surgery (ARS) for patients with gastroesophageal reflux disease (GERD): a systematic review of non-randomized studies. Gut. 2010;59(Suppl 1):A116–7.
    1. Rohof WO, Bisschops R, Tack J, Boeckxstaens GE. Postoperative problems 2011: fundoplication and obesity surgery. Gastroenterol Clin North Am. 2011;40:809–21. doi: 10.1016/j.gtc.2011.09.002.
    1. Richter JE. Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroenterol Hepatol. 2013;11:465–71. doi: 10.1016/j.cgh.2012.12.006.
    1. Lin DC, Chun CL, Triadafilopoulos G. Evaluation and management of patients with symptoms after anti-reflux surgery. Dis Esophagus. 2015;28:1–10. doi: 10.1111/dote.12103.
    1. Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbol DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014;31:625–30. doi: 10.1093/fampra/cmu050.
    1. Lodrup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol. 2013;48:515–22. doi: 10.3109/00365521.2012.746395.
    1. de Bortoli N, Guidi G, Martinucci I, et al. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study. Dis Esophagus. 2016;29:197–204. doi: 10.1111/dote.12319.
    1. Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of Gastroenterologists ACG Clinical Guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50. doi: 10.1038/ajg.2015.322.
    1. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–91. doi: 10.1053/j.gastro.2011.01.031.
    1. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42. doi: 10.1136/gutjnl-2013-305372.
    1. Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–37. doi: 10.1136/gutjnl-2013-305997.
    1. Akiyama J, Bertele A, Brock C, et al. Benign and precursor lesions in the esophagus. Ann N Y Acad Sci. 2014;1325:226–41. doi: 10.1111/nyas.12534.
    1. Malfertheiner P, Megraud F, O'Morain CA et al.; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut 2016; doi: 10.1136/gutjnl-2016-312288.
    1. World Gastroenterology Organisation Global Guidelines. GERD: Global Perspective on Gastroesophageal Reflux Disease. 2015. [last Accessed 30 Oct 2016].
    1. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42:649–63. doi: 10.1111/apt.13324.
    1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–28. doi: 10.1038/ajg.2012.444.
    1. Burgstaller JM, Jenni BF, Steurer J, Held U, Wertli MM. Treatment efficacy for non-cardiovascular chest pain: a systematic review and meta-analysis. PLoS One. 2014;9 doi: 10.1371/journal.pone.0104722.
    1. Roman C, Bruley des Varannes S, Muresan L, Picos A, Dumitrascu DL. Atrial fibrillation in patients with gastroesophageal reflux disease: a comprehensive review. World J Gastroenterol. 2014;20:9592–9. doi: 10.3748/wjg.v20.i23.7181.
    1. Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev. 2011;1
    1. Kahrilas PJ, Howden CW, Hughes N, Molloy-Bland M. Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease. Chest. 2013;143:605–12. doi: 10.1378/chest.12-1788.
    1. Sen P, Georgalas C, Bhattacharyya AK. A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux. Clin Otolaryngol. 2006;31:20–4. doi: 10.1111/j.1749-4486.2006.01134.x.
    1. Qadeer MA, Colabianchi N, Strome M, Vaezi MF. Gastroesophageal reflux and laryngeal cancer: causation or association? A critical review. Am J Otolaryngol. 2006;27:119–28. doi: 10.1016/j.amjoto.2005.07.010.
    1. Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil N. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25:385–92. doi: 10.1111/j.1365-2036.2006.03213.x.
    1. Guo H, Ma H, Wang J. Proton pump inhibitor therapy for the treatment of laryngopharyngeal reflux: a meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2016;50:295–300. doi: 10.1097/MCG.0000000000000324.
    1. Wei C. A meta-analysis for the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2016;273(11):3795–801. doi: 10.1007/s00405-016-4142-y.
    1. Liu C, Wang H, Liu K. Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux. Braz J Med Biol Res. 2016;49(7)
    1. Harding SM. Gastroesophageal reflux, asthma, and mechanisms of interaction. Am J Med. 2001;111(Suppl 8A):8S–12. doi: 10.1016/S0002-9343(01)00817-8.
    1. Scarpignato C. Pharmacological bases of the medical treatment of gastroesophageal reflux disease. Dig Dis. 1988;6:117–48. doi: 10.1159/000171190.
    1. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003;2
    1. Ranjitkar S, Smales RJ, Kaidonis JA. Oral manifestations of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2012;27:21–7. doi: 10.1111/j.1440-1746.2011.06945.x.
    1. Wilder-Smith CH, Wilder-Smith P, Kawakami-Wong H, Voronets J, Osann K, Lussi A. Quantification of dental erosions in patients with GERD using optical coherence tomography before and after double-blind, randomized treatment with esomeprazole or placebo. Am J Gastroenterol. 2009;104:2788–95. doi: 10.1038/ajg.2009.441.
    1. Hom C, Vaezi MF. Extra-esophageal manifestations of gastroesophageal reflux disease: diagnosis and treatment. Drugs. 2013;73:1281–95. doi: 10.1007/s40265-013-0101-8.
    1. Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65:524–31. doi: 10.1136/gutjnl-2015-310991.
    1. Kavitt RT, Hirano I, Vaezi MF. Diagnosis and treatment of eosinophilic esophagitis in adults. Am J Med. 2016;129:924–34. doi: 10.1016/j.amjmed.2016.04.024.
    1. Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology. 2009;137:1238–49. doi: 10.1053/j.gastro.2009.07.007.
    1. Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109:1503–12. doi: 10.1016/0016-5085(95)90637-1.
    1. Malagelada JR, Bazzoli F, Boeckxstaens G, et al. World Gastroenterology Organisation global guidelines: dysphagia - global guidelines and cascades update September 2014. J Clin Gastroenterol. 2015;49:370–8. doi: 10.1097/MCG.0000000000000307.
    1. Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE) Am J Gastroenterol. 2013;108:679–92. doi: 10.1038/ajg.2013.71.
    1. Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13–22. doi: 10.1016/j.cgh.2015.07.041.
    1. Molina-Infante J, Katzka DA, Gisbert JP. Review article: proton pump inhibitor therapy for suspected eosinophilic oesophagitis. Aliment Pharmacol Ther. 2013;37:1157–64. doi: 10.1111/apt.12332.
    1. Suzuki H, Hibi T. Novel effects other than antisecretory action and off-label use of proton pump inhibitors. Expert Opin Pharmacother. 2005;6:59–67. doi: 10.1517/14656566.6.1.59.
    1. Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54:2312–7. doi: 10.1007/s10620-009-0951-9.
    1. Molina-Infante J, Katzka DA. Proton-pump inhibitor-responsive esophageal eosinophilia. Curr Opin Gastroenterol. 2014;30:428–33. doi: 10.1097/MOG.0000000000000080.
    1. Molina-Infante J, Rivas MD, Hernandez-Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment Pharmacol Ther. 2014;40:955–65. doi: 10.1111/apt.12914.
    1. Katzka DA, Ravi K, Geno DM, et al. Endoscopic mucosal impedance measurements correlate with eosinophilia and dilation of intercellular spaces in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13:1242–8. doi: 10.1016/j.cgh.2014.12.032.
    1. van Malenstein H, Farre R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol. 2008;103:1021–8. doi: 10.1111/j.1572-0241.2007.01688.x.
    1. van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12:1815–23. doi: 10.1016/j.cgh.2014.02.037.
    1. Lucendo AJ, Arias A, Gonzalez-Cervera J, Olalla JM, Molina-Infante J. Dual response to dietary/topical steroid and proton pump inhibitor therapy in adult patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2016;137:931–4. doi: 10.1016/j.jaci.2015.07.033.
    1. Sodikoff J, Hirano I. Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. J Allergy Clin Immunol. 2016;137:631–3. doi: 10.1016/j.jaci.2015.07.008.
    1. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3–20. doi: 10.1016/j.jaci.2011.02.040.
    1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5. doi: 10.1016/S0140-6736(84)91816-6.
    1. Marshall BJ. The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. JAMA. 1995;274:1064–6. doi: 10.1001/jama.1995.03530130070032.
    1. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15:1949–58. doi: 10.1046/j.1365-2036.2001.01109.x.
    1. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev. 2003;4
    1. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004;99:1833–55. doi: 10.1111/j.1572-0241.2004.40014.x.
    1. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther. 2005;21:795–804. doi: 10.1111/j.1365-2036.2005.02418.x.
    1. Scarpignato C, Pelosini I. Antisecretory drugs for eradication of Helicobacter pylori: antimicrobial activity and synergism with antimicrobial agents. Progr Basic Clin Pharmacol. 1999;11:135–78.
    1. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587. doi: 10.1136/bmj.f4587.
    1. Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis. 2004;36:243–7. doi: 10.1016/j.dld.2004.01.004.
    1. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter. 1998;3:21–7. doi: 10.1046/j.1523-5378.1998.08024.x.
    1. Gatta L, Perna F, Figura N, et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J Antimicrob Chemother. 2003;51:439–42. doi: 10.1093/jac/dkg085.
    1. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut. 1998;43(Suppl 1):S56–60. doi: 10.1136/gut.43.2008.S56.
    1. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39:5–12. doi: 10.1093/jac/39.1.5.
    1. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC., Jr Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1989;8:888–9. doi: 10.1007/BF01963775.
    1. Parkman HP, Urbain JL, Knight LC, et al. Effect of gastric acid suppressants on human gastric motility. Gut. 1998;42:243–50. doi: 10.1136/gut.42.2.243.
    1. Goddard AF, Spiller RC. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol Ther. 1996;10:105–9. doi: 10.1111/j.1365-2036.1996.tb00183.x.
    1. Lieber CS. Gastritis and Helicobacter pylori: forty years of antibiotic therapy. Digestion. 1997;58:203–10. doi: 10.1159/000201445.
    1. Attumi TA, Graham DY. Follow-up testing after treatment of Helicobacter pylori infections: cautions, caveats, and recommendations. Clin Gastroenterol Hepatol. 2011;9:373–5. doi: 10.1016/j.cgh.2010.12.025.
    1. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999;116:248–53. doi: 10.1016/S0016-5085(99)70119-8.
    1. Wheeldon TU, Hoang TT, Phung DC, Bjorkman A, Granstrom M, Sorberg M. Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. Aliment Pharmacol Ther. 2003;18:93–100. doi: 10.1046/j.1365-2036.2003.01649.x.
    1. Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Dig Liver Dis. 2015;47:903–12. doi: 10.1016/j.dld.2015.06.010.
    1. Hunt R, Fallone C, Veldhuyzan van Zanten S, et al. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori - an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can J Gastroenterol. 2004;18:547–54. doi: 10.1155/2004/326767.
    1. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–25. doi: 10.1111/j.1572-0241.2007.01393.x.
    1. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–600. doi: 10.1111/j.1440-1746.2009.05982.x.
    1. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther. 2002;16:1149–56. doi: 10.1046/j.1365-2036.2002.01270.x.
    1. Sugimoto M, Graham DY. High-dose versus standard-dose PPI in triple therapy for Helicobacter pylori eradication. Nat Clin Pract Gastroenterol Hepatol. 2009;6:138–9. doi: 10.1038/ncpgasthep1353.
    1. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001;69:158–68. doi: 10.1067/mcp.2001.113959.
    1. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36:414–25. doi: 10.1111/j.1365-2036.2012.05211.x.
    1. McColl KE, Kennerley P. Proton pump inhibitors - differences emerge in hepatic metabolism. Dig Liver Dis. 2002;34:461–7. doi: 10.1016/S1590-8658(02)80102-5.
    1. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27–36. doi: 10.1046/j.1365-2036.1999.00022.x.
    1. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101:1467–75. doi: 10.1111/j.1572-0241.2006.00717.x.
    1. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One. 2013;8:e62162. doi: 10.1371/journal.pone.0062162.
    1. Kim JI, Park SH, Kim JK, Chung IS, Chung KW, Sun HS. The effects of nocturnal acid breakthrough on Helicobacter pylori eradication. Helicobacter. 2002;7:331–6. doi: 10.1046/j.1523-5378.2002.00105.x.
    1. Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12:317–23. doi: 10.1111/j.1523-5378.2007.00508.x.
    1. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol. 2003;17(Suppl B):36B–40. doi: 10.1155/2003/714124.
    1. Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdorffer E. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther. 1997;11:323–9. doi: 10.1046/j.1365-2036.1997.140316000.x.
    1. Zullo A, Ridola L, Francesco VD, et al. High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015;28:448–51.
    1. Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895–905. doi: 10.1016/j.cgh.2014.10.036.
    1. Furuta T, Sahara S, Ichikawa H, et al. Dual therapy with vonoprazan and amoxicillin is as effective as standard PPI-based triple therapy with amoxicillin and clarithromycin or metronidazole in Japan. Gastroenterology. 2016;150:S877.
    1. McColl KE. Helicobacter pylori negative ulcer disease. Dig Liver Dis. 2000;32:125–7. doi: 10.1016/S1590-8658(00)80398-9.
    1. Sbrozzi-Vanni A, Zullo A, Di Giulio E, et al. Low prevalence of idiopathic peptic ulcer disease: an Italian endoscopic survey. Dig Liver Dis. 2010;42:773–6. doi: 10.1016/j.dld.2010.03.019.
    1. Malfertheiner P, Chan FKL, McColl KEL. Peptic ulcer disease. Lancet. 2009;374:1449–61. doi: 10.1016/S0140-6736(09)60938-7.
    1. Hunt RH, Lanas A, Stichtenoth DO, Scarpignato C. Myths and facts in the use of anti-inflammatory drugs. Ann Med. 2009;41:423–37. doi: 10.1080/07853890902887295.
    1. McColl KE. How I, manage H. pylori-negative, NSAID/aspirin-negative peptic ulcers. Am J Gastroenterol. 2009;104:190–3. doi: 10.1038/ajg.2008.11.
    1. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic) Neuroendocrinology. 2006;84:173–82. doi: 10.1159/000098009.
    1. Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol. 2013;29:650–61. doi: 10.1097/MOG.0b013e328365efb1.
    1. Rehfeld JF, Federspiel B, Bardram L. A neuroendocrine tumor syndrome from cholecystokinin secretion. N Engl J Med. 2013;368:1165–6. doi: 10.1056/NEJMc1215137.
    1. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71. doi: 10.1210/jcem.86.12.8070.
    1. Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98–119. doi: 10.1159/000335591.
    1. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1) J Clin Endocrinol Metab. 2012;97:2990–3011. doi: 10.1210/jc.2012-1230.
    1. Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2009;10:1145–57. doi: 10.1517/14656560902887035.
    1. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 2000;118:696–704. doi: 10.1016/S0016-5085(00)70139-9.
    1. Ojeaburu JV, Ito T, Crafà P, Bordi C, Jensen RT. Mechanism of acid hypersecretion post curative gastrinoma resection. Dig Dis Sci. 2011;56:139–54. doi: 10.1007/s10620-010-1234-1.
    1. Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol. 2012;10:199–202. doi: 10.1016/j.cgh.2011.08.012.
    1. Nieto JM, Pisegna JR. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2006;7:169–75. doi: 10.1517/14656566.7.2.169.
    1. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4–19. doi: 10.1111/j.1742-7843.2006.pto_378.x.
    1. Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient. Nat Rev Gastroenterol Hepatol. 2015;12:98–107. doi: 10.1038/nrgastro.2014.235.
    1. Faisy C, Guerot E, Diehl JL, Iftimovici E, Fagon JY. Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. Intensive Care Med. 2003;29:1306–13. doi: 10.1007/s00134-003-1863-3.
    1. Quenot JP, Thiery N, Barbar S. When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care. 2009;15:139–43. doi: 10.1097/MCC.0b013e32832978e0.
    1. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56:347–79.
    1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228. doi: 10.1007/s00134-012-2769-8.
    1. Cook DJ, Griffith LE, Walter SD, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001;5:368–75. doi: 10.1186/cc1071.
    1. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996;275:308–14. doi: 10.1001/jama.1996.03530280060038.
    1. Krag M, Perner A, Wetterslev J, Wise MP, Hylander MM. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014;40:11–22. doi: 10.1007/s00134-013-3125-3.
    1. Liu B, Liu S, Yin A, Siddiqi J. Risks and benefits of stress ulcer prophylaxis in adult neurocritical care patients: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2015;19:409. doi: 10.1186/s13054-015-1107-2.
    1. Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med. 2004;32:2008–13. doi: 10.1097/01.CCM.0000142398.73762.20.
    1. Pongprasobchai S, Kridkratoke S, Nopmaneejumruslers C. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis. J Med Assoc Thai. 2009;92:632–7.
    1. Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41:693–705. doi: 10.1097/CCM.0b013e3182758734.
    1. Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107:507–20. doi: 10.1038/ajg.2011.474.
    1. Alshamsi F, Belley-Cote E, Cook D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20:120. doi: 10.1186/s13054-016-1305-6.
    1. Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med. 2010;38:1197–205. doi: 10.1097/CCM.0b013e3181d69ccf.
    1. Ro Y, Eun CS, Kim HS, et al. Risk of Clostridium difficile infection with the use of a proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Gut Liver. 2016;10:581–6. doi: 10.5009/gnl15324.
    1. Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med. 2010;38:2222–8. doi: 10.1097/CCM.0b013e3181f17adf.
    1. Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxis. World J Crit Care Med. 2016;5:57–64. doi: 10.5492/wjccm.v5.i1.57.
    1. Gardner TB, Robertson DJ. Stress ulcer prophylaxis in non-critically ill patients: less may be more. Am J Gastroenterol. 2006;101:2206–8. doi: 10.1111/j.1572-0241.2006.00847.x.
    1. Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag. 2015;11:649–57. doi: 10.2147/TCRM.S81759.
    1. Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373:1853–63. doi: 10.1056/NEJMra1501505.
    1. Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–92. doi: 10.1053/j.gastro.2016.02.011.
    1. Wang A, Liao X, Xiong L, et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol. 2008;8:43. doi: 10.1186/1471-230X-8-43.
    1. Noh YW, Jung HK, Kim SE, Jung SA. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J Neurogastroenterol Motil. 2010;16:148–56. doi: 10.5056/jnm.2010.16.2.148.
    1. Zagari RM, Law GR, Fuccio L, et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. Gastroenterology. 2010;138:1302–11. doi: 10.1053/j.gastro.2009.12.057.
    1. Hallas J, Bytzer P. Screening for drug related dyspepsia: an analysis of prescription symmetry. Eur J Gastroenterol Hepatol. 1998;10:27–32. doi: 10.1097/00042737-199801000-00006.
    1. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;2
    1. Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: What are we treating? Comment on “Helicobacter pylori eradication in functional dyspepsia”. Arch Intern Med. 2011;171:1936–7. doi: 10.1001/archinternmed.2011.541.
    1. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–67. doi: 10.1136/gutjnl-2015-309252.
    1. Lacy BE, Talley NJ, Locke GR, 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012;36:3–15. doi: 10.1111/j.1365-2036.2012.05128.x.
    1. Lassen AT, Hallas J, de Muckadell OB S. Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial. Gut. 2004;53:1758–63. doi: 10.1136/gut.2004.043570.
    1. Harvey RF, Lane JA, Nair P, et al. Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations - the Bristol Helicobacter Project. Aliment Pharmacol Ther. 2010;32:394–400. doi: 10.1111/j.1365-2036.2010.04363.x.
    1. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;4
    1. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004;127:1329–37. doi: 10.1053/j.gastro.2004.08.026.
    1. Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol. 2011;9:824–33. doi: 10.1016/j.cgh.2011.05.015.
    1. Scarpignato C, Pelosini I, Contini S. What is the effect of acid suppression with proton pump inhibitors on esophageal and gastric motility? In: Giuli R et al. Editor. The Duodenogastroesophageal Reflux – From the Duodenum to the Trachea: 125 Questions, 125 Answers. John Libbey Eurotext; 2006. pp. 262–71.
    1. McCallum RW, Zarling EJ, Goetsch AC, et al. Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease. Am J Med Sci. 2010;340:259–63. doi: 10.1097/MAJ.0b013e3181e9eea2.
    1. Aronson JK. Meyler's side effects of analgesic and anti-inflammatory drugs. Amsterdam: Elsevier; 2010.
    1. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am. 2010;39:433–64. doi: 10.1016/j.gtc.2010.08.010.
    1. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology. 2002;123:1006–12. doi: 10.1053/gast.2002.36013.
    1. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005;21:1411–8. doi: 10.1111/j.1365-2036.2005.02444.x.
    1. Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147:784–92. doi: 10.1053/j.gastro.2014.06.007.
    1. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:811–9. doi: 10.1038/ajg.2014.82.
    1. Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:42–50. doi: 10.1016/j.cgh.2014.06.021.
    1. Laporte S, Chapelle C, Caillet P, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2016. Ahead of print. doi: 10.1016/j.phrs.2016.08.017.
    1. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27:31–40. doi: 10.1111/j.1365-2036.2007.03541.x.
    1. Oka Y, Okamoto K, Kawashita N, Shirakuni Y, Takagi T. Meta-analysis of the risk of upper gastrointestinal hemorrhage with combination therapy of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs. Biol Pharm Bull. 2014;37:947–53. doi: 10.1248/bpb.b13-00885.
    1. Dall M, de Muckadell OB S, Moller Hansen J, Wildner-Christensen M, Touborg Lassen A, Hallas J. Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin reuptake inhibitors. Scand J Gastroenterol. 2011;46:1039–44. doi: 10.3109/00365521.2011.580100.
    1. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009;104:1475–82. doi: 10.1038/ajg.2009.128.
    1. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71:1565–75. doi: 10.4088/JCP.09r05786blu.
    1. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011;28:345–67. doi: 10.2165/11589340-000000000-00000.
    1. Targownik LE. Are we worried enough about selective serotonin receptor inhibitors and upper gastrointestinal bleeding? Clin Gastroenterol Hepatol. 2015;13:51–4. doi: 10.1016/j.cgh.2014.08.032.
    1. Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology Consensus Group Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29:481–96. doi: 10.1111/j.1365-2036.2008.03905.x.
    1. Scarpignato C, Pelosini I. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Ital J Gastroenterol Hepatol. 1999;31(Suppl 1):S63–72.
    1. Moore RA, Derry S, Phillips CJ, McQuay HJ. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (Coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006;7:79. doi: 10.1186/1471-2474-7-79.
    1. Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5:818–28. doi: 10.1016/j.cgh.2007.03.011.
    1. Blandizzi C, Tuccori M, Colucci R, et al. Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. Pharmacol Res. 2009;59:90–100. doi: 10.1016/j.phrs.2008.11.004.
    1. Yuan JQ, Tsoi KK, Yang M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016;43:1262–75. doi: 10.1111/apt.13642.
    1. Fujimori S, Takahashi Y, Tatsuguchi A, Sakamoto C. Omeprazole increased small intestinal mucosal injury in two of six disease-free cases evaluated by capsule endoscopy. Dig Endosc. 2014;26:676–9. doi: 10.1111/den.12188.
    1. Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol. 2016;14:809–15. e1. doi: 10.1016/j.cgh.2015.10.022.
    1. Marlicz W, Loniewski I, Grimes DS, Quigley EM. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc. 2014;89:1699–709. doi: 10.1016/j.mayocp.2014.07.015.
    1. Nagata N, Niikura R, Aoki T, et al. Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin. J Gastroenterol. 2015;50:1079–86. doi: 10.1007/s00535-015-1055-2.
    1. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. doi: 10.1136/bmj.c7086.
    1. Collaboration CatNTC. Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79. doi: 10.1016/S0140-6736(13)60900-9.
    1. Hunt RH, Choquette D, Craig BN, et al. Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs? Can Fam Physician. 2007;53:1177–84.
    1. Martinek J, Hlavova K, Zavada F, et al. "A surviving myth" - corticosteroids are still considered ulcerogenic by a majority of physicians. Scand J Gastroenterol. 2010;45:1156–61. doi: 10.3109/00365521.2010.497935.
    1. Filaretova L. Gastroprotective role of glucocorticoids during NSAID-induced gastropathy. Curr Pharm Des. 2013;19:29–33.
    1. Filaretova L. The hypothalamic-pituitary-adrenocortical system: Hormonal brain-gut interaction and gastroprotection. Auton Neurosci. 2006;125:86–93. doi: 10.1016/j.autneu.2006.01.005.
    1. Guslandi M. Steroid ulcers: any news? World J Gastrointest Pharmacol Ther. 2013;4:39–40.
    1. Luo JC, Chang FY, Lin HY, et al. The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. Aliment Pharmacol Ther. 2002;16:1241–8. doi: 10.1046/j.1365-2036.2002.01279.x.
    1. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001;153:1089–93. doi: 10.1093/aje/153.11.1089.
    1. Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut. 2000;46:27–31. doi: 10.1136/gut.46.1.27.
    1. Messer J, Reitman D, Sacks HS, Smith H, Jr, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med. 1983;309:21–4. doi: 10.1056/NEJM198307073090105.
    1. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735–40. doi: 10.7326/0003-4819-114-9-735.
    1. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–32. doi: 10.1111/j.1365-2796.1994.tb00855.x.
    1. Dorlo TP, Jager NG, Beijnen JH, Schellens JH. Concomitant use of proton pump inhibitors and systemic corticosteroids. Ned Tijdschr Geneeskd. 2013;157:A5540.
    1. Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2014;4 doi: 10.1136/bmjopen-2013-004587.
    1. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330:377–81. doi: 10.1056/NEJM199402103300601.
    1. Jansen A, Harenberg S, Grenda U, Elsing C. Risk factors for colonic diverticular bleeding: a Westernized community based hospital study. World J Gastroenterol. 2009;15:457–61. doi: 10.3748/wjg.15.457.
    1. Ogata T, Kamouchi M, Matsuo R, et al. Gastrointestinal bleeding in acute ischemic stroke: recent trends from the Fukuoka stroke registry. Cerebrovasc Dis Extra. 2014;4:156–64. doi: 10.1159/000365245.
    1. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197–202. doi: 10.1001/archinte.162.19.2197.
    1. US Preventive Services Task Force Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396–404. doi: 10.7326/0003-4819-150-6-200903170-00008.
    1. Zullo A, Hassan C, Campo SM, Morini S. Bleeding peptic ulcer in the elderly: risk factors and prevention strategies. Drugs Aging. 2007;24:815–28. doi: 10.2165/00002512-200724100-00003.
    1. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731–8. doi: 10.1136/gut.2005.080754.
    1. Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123:1108–15. doi: 10.1161/CIRCULATIONAHA.110.973008.
    1. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S3. doi: 10.1186/ar4175.
    1. Ahsberg K, Hoglund P, Stael von Holstein C. Mortality from peptic ulcer bleeding: the impact of comorbidity and the use of drugs that promote bleeding. Aliment Pharmacol Ther. 2010;32:801–10. doi: 10.1111/j.1365-2036.2010.04399.x.
    1. Ibanez L, Vidal X, Vendrell L, Moretti U, Laporte JR, Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006;23:235–42. doi: 10.1111/j.1365-2036.2006.02759.x.
    1. Schjerning Olsen AM, Lindhardsen J, Gislason GH, et al. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ. 2015;351:h5096. doi: 10.1136/bmj.h5096.
    1. Shiotani A, Murao T, Fujita Y, et al. Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding. PLoS One. 2013;8 doi: 10.1371/journal.pone.0084244.
    1. Lanas A, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2014;13:906–12. doi: 10.1016/j.cgh.2014.11.007.
    1. Chen M, Wei JF, Xu YN, Liu XJ, Huang DJ. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. Cardiovasc Ther. 2012;30:e227–33. doi: 10.1111/j.1755-5922.2011.00289.x.
    1. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34:1708–13. doi: 10.1093/eurheartj/eht042.
    1. Vaduganathan M, Cannon CP, Cryer BL, et al. Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial. Am J Med. 2016;129:1002–5. doi: 10.1016/j.amjmed.2016.03.042.
    1. Cardoso RN, Benjo AM, DiNicolantonio JJ, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015;2 doi: 10.1136/openhrt-2015-000248.
    1. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726. doi: 10.1136/.
    1. Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011;141:71–9. doi: 10.1053/j.gastro.2011.03.049.
    1. Trenk D. Proton pump inhibitors for prevention of bleeding episodes in cardiac patients with dual antiplatelet therapy - between Scylla and Charybdis? Int J Clin Pharmacol Ther. 2009;47:1–10. doi: 10.5414/CPP47001.
    1. Casado Arroyo R, Polo-Tomas M, Roncales MP, Scheiman J, Lanas A. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart. 2012;98:718–23. doi: 10.1136/heartjnl-2012-301632.
    1. Chan FK, Leung Ki EL, Wong GL, et al. Risks of bleeding recurrence and cardiovascular events with continued aspirin use after lower gastrointestinal hemorrhage. Gastroenterology. 2016;151:271–7. doi: 10.1053/j.gastro.2016.04.013.
    1. Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016. Ahead of print.
    1. Teichert M, van Noord C, Uitterlinden AG, et al. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol. 2011;153:379–85. doi: 10.1111/j.1365-2141.2011.08633.x.
    1. Berstad A. Does profound acid inhibition improve haemostasis in peptic ulcer bleeding? Scand J Gastroenterol. 1997;32:396–8. doi: 10.3109/00365529709007691.
    1. Geus WP. Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding? Scand J Gastroenterol. 2000;232:10–20.
    1. Green FW, Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology. 1978;74:38–43.
    1. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clot lysis by gastric juice: an in vitro study. Gut. 1989;30:1704–7. doi: 10.1136/gut.30.12.1704.
    1. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101–13. doi: 10.7326/0003-4819-152-2-201001190-00009.
    1. Andriulli A, Annese V, Caruso N, et al. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. Am J Gastroenterol. 2005;100:207–19. doi: 10.1111/j.1572-0241.2005.40636.x.
    1. Zed PJ, Loewen PS, Slavik RS, Marra CA. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother. 2001;35:1528–34. doi: 10.1345/aph.1A028.
    1. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2006;1
    1. Zhang YS, Li Q, He BS, Liu R, Li ZJ. Proton pump inhibitors therapy vs H2 receptor antagonists therapy for upper gastrointestinal bleeding after endoscopy: a meta-analysis. World J Gastroenterol. 2015;21:6341–51. doi: 10.3748/wjg.v21.i20.6341.
    1. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay - results from the Cochrane Collaboration. Aliment Pharmacol Ther. 2005;22:169–74. doi: 10.1111/j.1365-2036.2005.02546.x.
    1. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:286–96. doi: 10.1016/S0025-6196(11)61024-0.
    1. Sung JJ, Chan FK, Chen M, et al. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut. 2011;60:1170–7. doi: 10.1136/gut.2010.230292.
    1. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107:345–60. doi: 10.1038/ajg.2011.480.
    1. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47:a1–46. doi: 10.1055/s-0034-1393172.
    1. Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med. 2014;174:1755–62. doi: 10.1001/jamainternmed.2014.4056.
    1. Wang CH, Ma MH, Chou HC, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170:751–8. doi: 10.1001/archinternmed.2010.100.
    1. Tsoi KK, Hirai HW, Sung JJ. Meta-analysis: comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding. Aliment Pharmacol Ther. 2013;38:721–8. doi: 10.1111/apt.12441.
    1. Jian Z, Li H, Race NS, Ma T, Jin H, Yin Z. Is the era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers? Meta-analysis of the published literature. Br J Clin Pharmacol. 2016;82:880–9. doi: 10.1111/bcp.12866.
    1. Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS, Chan FK. Challenges in the management of acute peptic ulcer bleeding. Lancet. 2013;381:2033–43. doi: 10.1016/S0140-6736(13)60596-6.
    1. Freston J, Chiu YL, Pan WJ, Lukasik N, Taubel J. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Am J Gastroenterol. 2001;96:2058–65. doi: 10.1111/j.1572-0241.2001.03939.x.
    1. Pisegna JR, Sostek MB, Monyak JT, Miner PB., Jr Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults. Aliment Pharmacol Ther. 2008;27:483–90. doi: 10.1111/j.1365-2036.2007.03592.x.
    1. Wilder-Smith CH, Rohss K, Bondarov P, Hallerback B, Svedberg LE, Ahlbom H. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. Aliment Pharmacol Ther. 2004;20:1099–104. doi: 10.1111/j.1365-2036.2004.02272.x.
    1. Piccoli F, Ory G, Hadengue A, Beglinger C, Degen L. Effect of intravenous esomeprazole 40 mg and pantoprazole 40 mg on intragastric pH in healthy subjects. A prospective, open, randomised, two-way cross-over comparative study. Arzneimittelforschung. 2007;57:654–8.
    1. Hartmann D, Eickhoff A, Damian U, Riemann JF, Schilling D. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults. Eur J Gastroenterol Hepatol. 2007;19:133–7. doi: 10.1097/01.meg.0000252628.57925.32.
    1. Armstrong D, Bair D, James C, Tanser L, Escobedo S, Nevin K. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther. 2003;18:705–11. doi: 10.1046/j.1365-2036.2003.01743.x.
    1. Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009;150:455–64. doi: 10.7326/0003-4819-150-7-200904070-00105.
    1. Dorward S, Sreedharan A, Leontiadis GI, Howden CW, Moayyedi P, Forman D. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2006;4
    1. Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;7
    1. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol. 2006;33:106–20. doi: 10.1053/j.seminoncol.2005.12.001.
    1. Di Fiore F, Van Cutsem E. Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract Res Clin Gastroenterol. 2009;23:113–24. doi: 10.1016/j.bpg.2008.11.016.
    1. Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol. 2012;25:106–18.
    1. Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut. 2005;54:1051–4. doi: 10.1136/gut.2004.062596.
    1. Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Ann Oncol. 2009;20(Suppl 4):174–7.
    1. Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2011;4
    1. Andreyev HJ, Davidson SE, Gillespie C, Allum WH, Swarbrick E. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut. 2012;61:179–92. doi: 10.1136/gutjnl-2011-300563.
    1. McGuire DB, Fulton JS, Park J, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3165–77. doi: 10.1007/s00520-013-1942-0.
    1. Vehreschild MJ, Vehreschild JJ, Hubel K, et al. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Ann Oncol. 2013;24:1189–202. doi: 10.1093/annonc/mdt001.
    1. Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15:447–60. doi: 10.1016/S1470-2045(14)70006-3.
    1. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453–61. doi: 10.1002/cncr.28592.
    1. Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant. 2000;25:1269–78. doi: 10.1038/sj.bmt.1702447.
    1. Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40:409–21.
    1. Chaveli-Lopez B. Oral toxicity produced by chemotherapy: A systematic review. J Clin Exp Dent. 2014;6:e81–90. doi: 10.4317/jced.51337.
    1. Uwagawa T, Misawa T, Iida T, et al. Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients. J Palliat Med. 2010;13:815–8. doi: 10.1089/jpm.2009.0404.
    1. Sartori S, Nielsen I, Maestri A, Beltrami D, Trevisani L, Pazzi P. Acute gastroduodenal mucosal injury after cisplatin plus etoposide chemotherapy. Clinical and endoscopic study. Oncology. 1991;48:356–61. doi: 10.1159/000226958.
    1. Doria MI, Jr, Doria LK, Faintuch J, Levin B. Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine. A clinical and pathologic study. Cancer. 1994;73:2042–7. doi: 10.1002/1097-0142(19940415)73:8<2042::AID-CNCR2820730805>;2-A.
    1. Ravizza D, Fazio N, Fiori G, et al. Iatrogenic gastroduodenal ulcers during hepatic intra-arterial chemotherapy. Hepatogastroenterology. 2003;50:49–53.
    1. Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol. 2008;5:268–78. doi: 10.1038/ncponc1087.
    1. Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277–84. doi: 10.1007/s11912-012-0238-8.
    1. Tol J, Cats A, Mol L, et al. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs. 2008;26:393–7. doi: 10.1007/s10637-008-9125-4.
    1. Steer CB, Harper PG. Gastro-oesophageal complications in patients receiving cancer therapy: the role of proton pump inhibitors. Eur J Gastroenterol Hepatol. 2002;14(Suppl 1):S17–21.
    1. Xie YL, Huang QC. Advances in prevention and treatment of chemotherapy-induced gastrointestinal mucositis with proton pump inhibitors. World Chin J Digestology. 2014;22:642–7.
    1. Eguchi K, Suzuki M, Ida S, et al. Successful treatment of radiation-induced mucositis with proton pump inhibitor administration: A report of two laryngeal cancer cases. Auris Nasus Larynx. 2016. Ahead of print. .
    1. Sartori S, Trevisani L, Nielsen I, Tassinari D, Abbasciano V. Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study. Cancer. 1996;78:1477–82. doi: 10.1002/(SICI)1097-0142(19961001)78:7<1477::AID-CNCR15>;2-X.
    1. Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol. 2000;18:463–7.
    1. Triadafilopoulos G, Roorda AK, Akiyama J. Indications and safety of proton pump inhibitor drug use in patients with cancer. Expert Opin Drug Saf. 2013;12:659–72. doi: 10.1517/14740338.2013.797961.
    1. Mercadante S, David F, Riina S, Girelli D. Injustifiable use of gastroprotection in advanced cancer patients. Palliat Med. 2007;21:631–3. doi: 10.1177/0269216307082661.
    1. McCaleb RV, Gandhi AS, Clark SM, Clemmons AB. Clinical outcomes of acid suppressive therapy use in hematology/oncology patients at an Academic Medical Center. Ann Pharmacother. 2016;50:541–7. doi: 10.1177/1060028016644469.
    1. WHO: Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. [last Accessed 30 Oct 2016].
    1. Lugini L, Federici C, Borghi M, et al. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J Enzyme Inhib Med Chem. 2016;31:538–45.
    1. Taylor S, Spugnini EP, Assaraf YG, Azzarito T, Rauch C, Fais S. Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat. 2015;23:69–78. doi: 10.1016/j.drup.2015.08.004.
    1. Fais S. Evidence-based support for the use of proton pump inhibitors in cancer therapy. J Transl Med. 2015;13:368. doi: 10.1186/s12967-015-0735-2.
    1. Papagerakis S, Bellile E, Peterson LA, et al. Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res. 2014;7:1258–69. doi: 10.1158/1940-6207.CAPR-14-0002.
    1. Lodato F, Azzaroli F, Di Girolamo M, et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol. 2008;14:2980–5. doi: 10.3748/wjg.14.2980.
    1. Savarino V, Mela GS, Zentilin P, et al. Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. J Hepatol. 1996;25:152–7. doi: 10.1016/S0168-8278(96)80067-5.
    1. Yang J, Guo Z, Wu Z, Wang Y. Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients. Cochrane Database Syst Rev. 2008;2
    1. Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010;53:849–55. doi: 10.1016/j.jhep.2010.05.017.
    1. Bajaj JS, Cox IJ, Betrapally NS, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014;307:G951–7. doi: 10.1152/ajpgi.00268.2014.
    1. Lo EA, Wilby KJ, Ensom MH. Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review. Ann Pharmacother. 2015;49:207–19. doi: 10.1177/1060028014559244.
    1. Deshpande A, Pasupuleti V, Thota P, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28:235–42. doi: 10.1111/jgh.12065.
    1. Yu T, Tang Y, Jiang L, Zheng Y, Xiong W, Lin L. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis. Dig Liver Dis. 2016;48:353–9. doi: 10.1016/j.dld.2015.12.009.
    1. Xu HB, Wang HD, Li CH, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res. 2015;14:7490–501. doi: 10.4238/2015.July.3.25.
    1. Tsai CF, Chen MH, Wang YP, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in population study. Gastroenterology. 2016. Ahead of print.
    1. Terg R, Casciato P, Garbe C, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study. J Hepatol. 2015;62:1056–60. doi: 10.1016/j.jhep.2014.11.036.
    1. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252–61. doi: 10.1053/j.gastro.2013.01.068.
    1. Working Party of the British Society of Gastroenterology. Association of Surgeons of Great Britain and Ireland. Pancreatic Society of Great Britain and Ireland. Association of Upper GI Surgeons of Great Britain and Ireland UK guidelines for the management of acute pancreatitis. Gut. 2005;54 Suppl 3:iii1–9.
    1. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis - 2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–11. doi: 10.1136/gutjnl-2012-302779.
    1. Cavallini G, Frulloni L, Bassi C, et al. Prospective multicentre survey on acute pancreatitis in Italy (ProInf-AISP): results on 1005 patients. Dig Liver Dis. 2004;36:205–11. doi: 10.1016/j.dld.2003.11.027.
    1. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. Gastroenterology. 2007;132:1127–51. doi: 10.1053/j.gastro.2007.01.055.
    1. Kambhampati S, Park W, Habtezion A. Pharmacologic therapy for acute pancreatitis. World J Gastroenterol. 2014;20:16868–80. doi: 10.3748/wjg.v20.i45.16868.
    1. Chey WY, Chang TM. Secretin: historical perspective and current status. Pancreas. 2014;43:162–82. doi: 10.1097/01.mpa.0000437325.29728.d6.
    1. Cai J, Zhou W, Luo HS, Peng LV. Effect of proton pump inhibitor on amylase release from isolated pancreatic acini. In Vitro Cell Dev Biol Anim. 2007;43:25–7. doi: 10.1007/s11626-006-9004-2.
    1. Hackert T, Tudor S, Felix K, et al. Effects of pantoprazole in experimental acute pancreatitis. Life Sci. 2010;87:551–7. doi: 10.1016/j.lfs.2010.09.008.
    1. Yoo JH, Kwon C-I, Yoo K-H, et al. Effect of proton pump inhibitor in patients with acute pancreatitis - pilot study. Korean J Gastroenterol. 2012;60:362. doi: 10.4166/kjg.2012.60.6.362.
    1. Murata A, Ohtani M, Muramatsu K, Matsuda S. Effects of proton pump inhibitor on outcomes of patients with severe acute pancreatitis based on a national administrative database. Pancreatology. 2015;15:491–6. doi: 10.1016/j.pan.2015.07.006.
    1. Abdelfatah MM, Nayfe R, El Zoghbi M, Gallegos P, Shill M, Kandil H. Proton pump inhibitors impact on post-endoscopic retrograde cholangio-pancreatography pancreatitis. Pancreas. 2015;44:680–1. doi: 10.1097/MPA.0000000000000302.
    1. Pezzilli R, Zerbi A, Campra D, et al. Italian Association for the Study of the Pancreas (AISP). Consensus guidelines on severe acute pancreatitis. Dig Liver Dis. 2015;47:532–43. doi: 10.1016/j.dld.2015.03.022.
    1. Takeda K, Takada T, Kawarada Y, et al. JPN Guidelines for the management of acute pancreatitis: medical management of acute pancreatitis. J Hepatobiliary Pancreat Surg. 2006;13:42–7. doi: 10.1007/s00534-005-1050-8.
    1. Majumder S, Chari ST. Chronic pancreatitis. Lancet. 2016;387:1957–66. doi: 10.1016/S0140-6736(16)00097-0.
    1. Braganza JM, Lee SH, McCloy RF, McMahon MJ. Chronic pancreatitis. Lancet. 2011;377:1184–97. doi: 10.1016/S0140-6736(10)61852-1.
    1. Rickels MR, Bellin M, Toledo FG, et al. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology. 2013;13:336–42. doi: 10.1016/j.pan.2013.05.002.
    1. Meier JJ, Giese A. Diabetes associated with pancreatic diseases. Curr Opin Gastroenterol. 2015;31:400–6. doi: 10.1097/MOG.0000000000000199.
    1. Brown A, Hughes M, Tenner S, Banks PA. Does pancreatic enzyme supplementation reduce pain in patients with chronic pancreatitis: a meta-analysis. Am J Gastroenterol. 1997;92:2032–5.
    1. Lieb JG, 2nd, Forsmark CE. Review article: pain and chronic pancreatitis. Aliment Pharmacol Ther. 2009;29:706–19. doi: 10.1111/j.1365-2036.2009.03931.x.
    1. Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gastroenterol. 2011;4:55–73.
    1. Dominguez-Munoz JE. Chronic pancreatitis and persistent steatorrhea: what is the correct dose of enzymes? Clin Gastroenterol Hepatol. 2011;9:541–6. doi: 10.1016/j.cgh.2011.02.027.
    1. Geus WP, Eddes EH, Gielkens HA, Gan KH, Lamers CB, Masclee AA. Post-prandial intragastric and duodenal acidity are increased in patients with chronic pancreatitis. Aliment Pharmacol Ther. 1999;13:937–43. doi: 10.1046/j.1365-2036.1999.00543.x.
    1. DiMagno EP. Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency. Best Pract Res Clin Gastroenterol. 2001;15:477–86. doi: 10.1053/bega.2001.0195.
    1. Anthony H, Collins CE, Davidson G, et al. Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Pediatric Gastroenterological Society and the Dietitians Association of Australia. J Paediatr Child Health. 1999;35:125–9. doi: 10.1046/j.1440-1754.1999.00363.x.
    1. Frulloni L, Falconi M, Gabbrielli A, et al. Italian consensus guidelines for chronic pancreatitis. Dig Liver Dis. 2010;42(Suppl 6):S381–406. doi: 10.1016/S1590-8658(10)60682-2.
    1. Toouli J, Biankin AV, Oliver MR, Pearce CB, Wilson JS, Wray NH. Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. Med J Aust. 2010;193:461–7.
    1. Pezzilli R, Andriulli A, Bassi C, et al. Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas. World J Gastroenterol. 2013;19:7930–46. doi: 10.3748/wjg.v19.i44.7930.
    1. Hoffmeister A, Mayerle J, Beglinger C, et al. English language version of the S3-consensus guidelines on chronic pancreatitis: definition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. Z Gastroenterol. 2015;53:1447–95. doi: 10.1055/s-0041-107379.
    1. de-Madaria E, Abad-Gonzalez A, Aparicio JR, et al. The Spanish Pancreatic Club's recommendations for the diagnosis and treatment of chronic pancreatitis: part 2 (treatment) Pancreatology. 2013;13:18–28. doi: 10.1016/j.pan.2012.11.310.
    1. Delhaye M, Van Steenbergen W, Cesmeli E, et al. Belgian consensus on chronic pancreatitis in adults and children: statements on diagnosis and nutritional, medical, and surgical treatment. Acta Gastroenterol Belg. 2014;77:47–65.
    1. Gheorghe C, Seicean A, Saftoiu A, et al. Romanian guidelines on the diagnosis and treatment of exocrine pancreatic insufficiency. J Gastrointestin Liver Dis. 2015;24:117–23.
    1. Ito T, Ishiguro H, Ohara H, et al. Evidence-based clinical practice guidelines for chronic pancreatitis 2015. J Gastroenterol. 2016;51:85–92. doi: 10.1007/s00535-015-1149-x.
    1. Berry AJ. Pancreatic enzyme replacement therapy during pancreatic insufficiency. Nutr Clin Pract. 2014;29:312–21. doi: 10.1177/0884533614527773.
    1. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323–30. doi: 10.3748/wjg.v16.i19.2323.
    1. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448–57. doi: 10.1007/s11894-010-0141-0.
    1. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931–50. doi: 10.1007/s10620-010-1560-3.
    1. Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012;46:93–114. doi: 10.1097/MCG.0b013e3182333820.
    1. Johnson DA, Oldfield EC., 4th Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol. 2013;11:458–64. doi: 10.1016/j.cgh.2012.11.031.
    1. de la Coba OC, Arguelles Arias F, Martin de Argila de Prados C, et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Espanola de Patologia Digestiva. Rev Esp Enferm Dig. 2016;108:207–24. doi: 10.17235/reed.2016.4232/2016.
    1. Mossner J. The indications, applications, and risks of proton pump inhibitors. Dtsch Arztebl Int. 2016;113:477–83.
    1. Lahner E, Annibale B, Delle FG. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther. 2009;29:1219–29. doi: 10.1111/j.1365-2036.2009.03993.x.
    1. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29:769–84. doi: 10.2165/00002018-200629090-00002.
    1. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37:201–11. doi: 10.1007/s40264-014-0144-0.
    1. Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Safe. 2016;15:223–36. doi: 10.1517/14740338.2016.1128413.
    1. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935–51. doi: 10.1007/s00228-008-0538-y.
    1. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913–58. doi: 10.2165/00003088-200241120-00002.
    1. Leontiadis GI, Yuan Y, Howden CW. The interaction between proton pump inhibitors and clopidogrel and upper gastrointestinal bleeding. Gastrointest Endosc Clin N Am. 2011;21:637–56. doi: 10.1016/j.giec.2011.07.005.
    1. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleve Clin J Med. 2011;78:39–49. doi: 10.3949/ccjm.77a.10087.
    1. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–17. doi: 10.1056/NEJMoa1007964.
    1. Vaduganathan M, Bhatt DL, Cryer BL, et al. Proton-pump inhibitors reduce gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy. J Am Coll Cardiol. 2016;67:1661–71. doi: 10.1016/j.jacc.2015.12.068.
    1. Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41:1162–74. doi: 10.1111/apt.13194.
    1. Fiocca R, Mastracci L, Attwood SE, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther. 2012;36:959–71. doi: 10.1111/apt.12052.
    1. Huang JQ, Hunt RH. Eradication of Helicobacter pylori infection in the management of patients with dyspepsia and non-ulcer dyspepsia. Yale J Biol Med. 1998;71:125–33.
    1. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134:1842–60. doi: 10.1053/j.gastro.2008.05.021.
    1. Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 2010;49:2561–8. doi: 10.2169/internalmedicine.49.4064.
    1. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115–27. doi: 10.1053/j.gastro.2010.08.023.
    1. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16:e228–34.
    1. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol. 2009;104(Suppl 2):S27–32. doi: 10.1038/ajg.2009.49.
    1. Shin JM, Vagin O, Munson K, Kidd M, Modlin IM, Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci. 2008;65:264–81. doi: 10.1007/s00018-007-7249-x.
    1. Nealis TB, Howden CW. Is there a dark side to long-term proton pump inhibitor therapy? Am J Ther. 2008;15:536–42. doi: 10.1097/MJT.0b013e31817149bf.
    1. Flower R. The Osler Lecture 2012: 'Pharmacology 2.0, medicines, drugs and human enhancement'. QJM. 2012;105:823–30. doi: 10.1093/qjmed/hcs105.
    1. Jepsen P, Johnsen SP, Gillman MW, Sorensen HT. Interpretation of observational studies. Heart. 2004;90:956–60. doi: 10.1136/hrt.2003.017269.
    1. Laine L. Clinical Practice. Upper gastrointestinal bleeding due to a peptic ulcer. N Engl J Med. 2016;374:2367–76. doi: 10.1056/NEJMcp1514257.
    1. Steinbrook R. Guidance for guidelines. N Engl J Med. 2007;356:331–3. doi: 10.1056/NEJMp068282.
    1. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527–30. doi: 10.1136/bmj.318.7182.527.
    1. Dries AM, Richardson P, Cavazos J, Abraham NS. Therapeutic intent of proton pump inhibitor prescription among elderly nonsteroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 2009;30:652–61. doi: 10.1111/j.1365-2036.2009.04085.x.
    1. Lanas A, Boers M, Nuevo J. Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann Rheum Dis. 2015;74:675–81. doi: 10.1136/annrheumdis-2013-204155.
    1. Pasina L, Urru SA, Mandelli S, Giua C, Minghetti P. Evidence-based and unlicensed indications for proton pump inhibitors and patients' preferences for discontinuation: a pilot study in a sample of Italian community pharmacies. J Clin Pharm Ther. 2016;41:220–3. doi: 10.1111/jcpt.12371.
    1. Issa IA, Soubra O, Nakkash H, Soubra L. Variables associated with stress ulcer prophylaxis misuse: a retrospective analysis. Dig Dis Sci. 2012;57:2633–41. doi: 10.1007/s10620-012-2104-9.
    1. Hong MT, Monye LC, Seifert CF. Acid suppressive therapy for stress ulcer prophylaxis in noncritically ill patients. Ann Pharmacother. 2015;49:1004–8. doi: 10.1177/1060028015592014.
    1. Redfern RE, Brown M, Karhoff KL, Middleton JL. Overuse of acid-suppression therapy at an urban tertiary hospital. South Med J. 2015;108:732–8. doi: 10.14423/SMJ.0000000000000383.
    1. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007;64:1396–400. doi: 10.2146/ajhp060393.
    1. Meli M, Malta R, Aprea L, et al. Proton pump inhibitor use in a university teaching hospital [in Italian] Italian J Med. 2012;6:202–9. doi: 10.1016/j.itjm.2012.06.001.
    1. Sheikh I, Waghray A, Waghray N, Dong C, Wolfe MM. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2014;109:789–94. doi: 10.1038/ajg.2013.421.
    1. Menees SB, Guentner A, Chey SW, Saad R, Chey WD. How do US gastroenterologists use over-the-counter and prescription medications in patients with gastroesophageal reflux and chronic constipation? Am J Gastroenterol. 2015;110:1516–25. doi: 10.1038/ajg.2015.156.
    1. Blandizzi C, Scarpignato C. Generic drugs in gastroenterology. Critical issues in bioequivalence and inference in therapeutic equivalence. Ther Perspect. 2014;17:1–43.
    1. Holtmann G, Bigard MA, Malfertheiner P, Pounder R. Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD. Int J Clin Pharm. 2011;33:493–500. doi: 10.1007/s11096-011-9489-y.
    1. Galmiche JP, Stephenson K. Treatment of gastroesophageal reflux disease in adults: an individualized approach. Dig Dis. 2004;22:148–60. doi: 10.1159/000080314.
    1. Lee TJ, Fennerty MB, Howden CW. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Aliment Pharmacol Ther. 2004;20:1241–51. doi: 10.1111/j.1365-2036.2004.02289.x.
    1. Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98:S40–8. doi: 10.1016/S0002-9270(03)00014-5.
    1. Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther. 2005;21:1299–312. doi: 10.1111/j.1365-2036.2005.02490.x.
    1. Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther. 2007;26:195–204. doi: 10.1111/j.1365-2036.2007.03381.x.
    1. Metz DC, Inadomi JM, Howden CW, van Zanten SJ, Bytzer P. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol. 2007;102:642–53. doi: 10.1111/j.1572-0241.2006.00998.x.
    1. Contini S, Scarpignato C. Endoscopic treatment of gastro-oesophageal reflux disease (GORD): a systematic review. Dig Liver Dis. 2003;35:818–38. doi: 10.1016/S1590-8658(03)00449-3.
    1. Lundell L. Surgical therapy of gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2010;24:947–59. doi: 10.1016/j.bpg.2010.09.006.
    1. Worrell SG, Greene CL, DeMeester TR. The state of surgical treatment of gastroesophageal reflux disease after five decades. J Am Coll Surg. 2014;219:819–30. doi: 10.1016/j.jamcollsurg.2014.05.018.
    1. Thompson W, Hogel M, Li Y, et al. Effect of a proton pump inhibitor deprescribing guideline on drug usage and costs in long-term care. J Am Med Dir Assoc. 2016;17:673. e1–4. doi: 10.1016/j.jamda.2016.04.020.
    1. Wallace JL. Selective cyclooxygenase-2 inhibitors: after the smoke has cleared. Dig Liver Dis. 2002;34:89–94. doi: 10.1016/S1590-8658(02)80234-1.
    1. Moss SF, Playford RJ, Ayesu K, Li SK, Calam J. pH-dependent secretion of gastrin in duodenal ulcer disease: effect of suppressing Helicobacter pylori. Digestion. 1992;52:173–8. doi: 10.1159/000200950.
    1. Eslami L, Nasseri-Moghaddam S. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions? Arch Iran Med. 2013;16:449–58.
    1. Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol. 2013;19:2560–8. doi: 10.3748/wjg.v19.i16.2560.
    1. Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016. Ahead of print. doi: 10.1016/j.cgh.2016.05.018.
    1. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133:755–60. doi: 10.1053/j.gastro.2007.06.014.
    1. Free Martin FC, Chenevix-Trench G, Yeomans ND. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther. 2016;44:915–25. doi: 10.1111/apt.13800.
    1. Bradley MC, Murray LJ, Cantwell MM, Hughes CM. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study. Br J Cancer. 2012;106:233–9. doi: 10.1038/bjc.2011.511.
    1. Lai SW, Sung FC, Lin CL, Liao KF. Use of proton pump inhibitors correlates with increased risk of pancreatic cancer: a case-control study in Taiwan. Kuwait Med J. 2014;46:44–8.
    1. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34:1269–81. doi: 10.1111/j.1365-2036.2011.04874.x.
    1. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:381–90. doi: 10.1038/ajg.2015.22.
    1. Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One. 2012;7 doi: 10.1371/journal.pone.0050836.
    1. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56. doi: 10.1111/j.1572-0241.2007.01275.x.
    1. Daniell HW. Acid suppressing therapy as a risk factor for Candida esophagitis. Dis Esophagus. 2016;29:479–83. doi: 10.1111/dote.12354.
    1. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:483–90. doi: 10.1016/j.cgh.2012.12.011.
    1. Lebwohl B, Spechler SJ, Wang TC, Green PH, Ludvigsson JF. Use of proton pump inhibitors and subsequent risk of celiac disease. Dig Liver Dis. 2014;46:36–40. doi: 10.1016/j.dld.2013.08.128.
    1. Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34:771–85. doi: 10.1016/j.cll.2014.08.008.
    1. Scarpignato C, Bertelé A. Effect of proton pump inhibitors on gut microbiota. Biotascope. 2016. In press.
    1. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52:144–53. doi: 10.1053/j.ajkd.2008.03.004.
    1. Jung SB, Nagaraja V, Kapur A, Eslick GD. Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis. Intern Med J. 2015;45:409–16. doi: 10.1111/imj.12697.
    1. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37:1237–41. doi: 10.3109/0886022X.2015.1057800.
    1. Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One. 2014;9 doi: 10.1371/journal.pone.0112558.
    1. Capurso G, Marignani M, Attilia F, et al. Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospective case-series and systematic review of the literature. Dig Liver Dis. 2011;43:380–5. doi: 10.1016/j.dld.2010.11.015.
    1. Tong J, Zheng Q, Zhang C, Lo R, Shen J, Ran Z. Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:265–76. doi: 10.1038/ajg.2014.431.
    1. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10 doi: 10.1371/journal.pone.0128004.
    1. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183:310–9. doi: 10.1503/cmaj.092129.
    1. Lau AN, Tomizza M, Wong-Pack M, Papaioannou A, Adachi JD. The relationship between long-term proton pump inhibitor therapy and skeletal frailty. Endocrine. 2015;49:606–10. doi: 10.1007/s12020-015-0576-z.
    1. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319–26. doi: 10.1503/cmaj.071330.
    1. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209–18. doi: 10.1038/ajg.2011.113.
    1. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124:519–26. doi: 10.1016/j.amjmed.2011.01.007.
    1. Badiola N, Alcalde V, Pujol A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8 doi: 10.1371/journal.pone.0058837.
    1. Booker A, Jacob LE, Rapp M, Bohlken J, Kostev K. Risk factors for dementia diagnosis in German primary care practices. Int Psychogeriatr. 2016;28:1059–65. doi: 10.1017/S1041610215002082.
    1. Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–6. doi: 10.1001/jamaneurol.2015.4791.
    1. Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419–28. doi: 10.1007/s00406-014-0554-0.
    1. Otremba I, Wilczynski K, Szewieczek J. Delirium in the geriatric unit: proton-pump inhibitors and other risk factors. Clin Interv Aging. 2016;11:397–405.
    1. Ghebremariam YT, Cooke JP, Khan F, et al. Proton pump inhibitors and vascular function: A prospective cross-over pilot study. Vasc Med. 2015;20:309–16. doi: 10.1177/1358863X14568444.
    1. Chan JL, El-Serag HB. Is proton pump inhibitor use associated with risk of myocardial infarction? Gastroenterology. 2016;150:526–7. doi: 10.1053/j.gastro.2015.12.016.
    1. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10 doi: 10.1371/journal.pone.0124653.
    1. Turkiewicz A, Vicente RP, Ohlsson H, Tyden P, Merlo J. Revising the link between proton-pump inhibitors and risk of acute myocardial infarction-a case-crossover analysis. Eur J Clin Pharmacol. 2015;71:125–9. doi: 10.1007/s00228-014-1779-6.
    1. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545–53. doi: 10.1111/j.1365-2036.2007.03407.x.
    1. Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016;29(5):611–6. doi: 10.1007/s40620-016-0309-2.
    1. Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol. 2006;62:473–9. doi: 10.1007/s00228-006-0131-1.
    1. Duncan SJ, Howden CW. Proton pump inhibitors and risk of rhabdomyolysis: a comprehensive review. Drug Saf. 2016. In press.
    1. Bergmann M, Guignard B, Ribi C. Hypersensitivity to proton pump inhibitors. Rev Med Suisse. 2012;8:830–5.
    1. Savarino V, Dulbecco P, de Bortoli N, et al. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med. 2016

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj